|
Lawrence Corey (born February 14, 1947), is a member of the vaccine and infectious disease division and President and Director Emeritus of Fred Hutchinson Cancer Research Center in Seattle, Washington. He also serves as founding director and co-principal investigator of the HIV Vaccine Trials Network.〔 In addition, Corey is professor of medicine and laboratory medicine at the University of Washington. The American physician-scientist is an internationally recognized expert in virology, immunology and vaccine development. His discoveries over the past 30 years are cited as having deepened the understanding of both the pathogenesis and treatment of diseases caused by viruses, especially human immunodeficiency virus (HIV) and herpesviruses. Corey has pioneered some of the most significant advances in the creation of safe and effective antivirals for herpes viruses, HIV, and hepatitis infections, the testing of experimental vaccines for HIV and genital herpes, and the designing of new methods for diagnosing and monitoring therapies for viral infections. ==Education and career== Corey received a B.A. and M.D. from the University of Michigan, and received postgraduate training at the University of Michigan, University of Washington, and the U. S. Centers for Disease Control and Prevention. In the early 1980s Corey worked with Nobel Prize-winning biochemist and pharmacologist Dr. Gertrude Elion to demonstrate that an antiviral that was selective and specific for a viral-specified enzyme could be safely and effectively administered to control a chronic viral infection (herpes simplex virus-2). These studies were directly responsible for the subsequent successful quest of the pharmaceutical and medical sciences communities to develop effective antiviral therapy for hepatitis B and HIV.〔 In 1987 Corey directed the AIDS Clinical Trials Group, or ACTG, which conducted pivotal clinical trials confirming the use of the antiretroviral drug AZT to reduce maternal-fetal transmission of HIV and the usefulness of highly active antiretroviral therapy (HAART).〔 His research group was the first to identify an association between the virus that causes genital herpes (herpes simplex virus) and HIV. Through the ACTG he also was the first to lead the integration of community members into clinical research activities. In the mid-1990s, Corey increasingly focused his work in the area of vaccine development, and in 1998 worked with the US National Institute of Allergy and Infectious Diseases to develop a global clinical trials group to speed the development of HIV vaccines. In 2002, Corey became the major driver in conceiving of the Global HIV Vaccine Enterprise. The Enterprise is one of the few scientific programs that is overseen by leaders of the major industrialized countries of the world.〔 In July 2008, Dr. Corey co-founded the biotechnology company Immune Design, to develop vaccines built on emerging understanding of the human immune system. The Company's additional founders include Dr. David Baltimore, Nobel Laureate, former president of Caltech, and a leading immunologist; Dr. Steven Reed, founder of the Infectious Disease Research Institute (IDRI), Dr. Lili Yang of Caltech, and Dr. Pin Wang of University of Southern California. On July 30, 2010, Dr Corey was named the fourth president of the Fred Hutchinson Cancer Research Center. One of Corey’s major scientific initiatives has been to study and develop better therapy for the treatment and prevention of infectious disease associated cancers such as Kaposi sarcoma and Burkitt lymphoma In the mid 2000s, that led Corey to launch a partnership between Fred Hutchinson Cancer Research Center and the Uganda Cancer Institute. In May 2015, that partnership led to the opening of the first comprehensive cancer center jointly constructed by U.S. and African institutions in sub-Saharan Africa. Corey also was a cofounder of Juno Therapeutics, a company devoted to using genetically engineered T cells to fight cancer. Corey started his career at the University of Washington, became a full professor at the institution at age 37 and is currently holder of the Lawrence Corey Endowed Chair in Medical Virology at the University of Washington.〔 In 2008, he was elected to the Institute of Medicine of the National Academy of Sciences. He has authored 12 books and more than 690 scientific publications. He has been a member of numerous scientific committees and editorial boards, having served on the Board of Counselors for both the National Cancer Institute and National Institute of Allergy and Infectious Diseases.〔 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Lawrence Corey」の詳細全文を読む スポンサード リンク
|